Zimmer Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Zimmer Partners’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,500	Closed	-$354K	–	148
2020 Q2	$354K	Buy	+10,500	New	+$335K	﹤0.01%	106

Other funds holding ORIC

Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Zimmer Partners's ORIC Position: Q3 2020 in Review

Zimmer Partners sold out of Oric Pharmaceuticals (ORIC) in Q3 2020, closing a stake of 10,500 shares — an estimated $354K sold.

Zimmer Partners first reported a position in ORIC in Q2 2020 and held it in 1 quarter. The position peaked at $354K in Q2 2020. 54 funds tracked by Wall St. Rank hold ORIC as of Q3 2020.

Zimmer Partners reported no remaining Oric Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Zimmer Partners sold 10,500 Oric Pharmaceuticals shares in Q3 2020, an estimated $354K.
Zimmer Partners first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 1 quarter.
Zimmer Partners's Oric Pharmaceuticals position peaked at $354K in Q2 2020.
54 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2020.

Based on Zimmer Partners's 13F filing for Q3 2020, filed 16 Nov 2020.